Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRR1 | P24046 | 2/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 2/20 | 0.30 |
| ▸ | CACNB3 | P54284 | 1/20 | 0.30 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.30 |
| ▸ | PGR | P06401 | 1/20 | 0.30 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.30 |
| ▸ | HTR2B | P41595 | 1/20 | 0.30 |
| ▸ | CACNA2D2 | Q9NY47 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Negamycin SCHEMBL21578042 | 1.00 | GABRR1 (0.38) | GABRR1LMNACACNA2D1CACNB3CACNA1C | |
| Negamycin SCHEMBL564074 | 1.00 | GABRR1 (0.38) | GABRR1LMNACACNA2D1CACNB3CACNA1C | |
| SCHEMBL16285773 | 0.86 | KDM7A (0.32) | GABRR1LMNACACNA2D1CACNB3CACNA1C | |
| SCHEMBL24176384 | 0.85 | CACNA2D1 (0.30) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL25466927 | 0.85 | CACNA2D1 (0.30) | CACNA2D1CACNB3CACNA1CPGRADRA1A | |
| SCHEMBL21577900 | 0.83 | GABRR1 (0.36) | GABRR1LMNA | |
| SCHEMBL21577991 | 0.82 | — | — | |
| SCHEMBL22005471 | 0.82 | — | — | |
| SCHEMBL16279005 | 0.80 | GABRR1 (0.32) | GABRR1 | |
| SCHEMBL16279002 | 0.80 | GABRR1 (0.32) | GABRR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-58113161-A | — | — | None | — | — | JP | disclosed |
| US-20230381152-A1 | METHODS FOR TREATING COLON CANCER WITH COMPOSITIONS COMPRISING AMLEXANOX AND IMMUNE CHECKPOINT INHIBITORS | MOONSHOT PHARMA LLC (US) | 2023-11-30 | — | — | US | disclosed |
| US-11654135-B2 | Methods for treating colon cancer with compositions comprising amlexanox and immune checkpoint inhibitors | MOONSHOT PHARMA LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-7927613-B2 | Pharmaceutical co-crystal compositions | UNIVERSITY OF SOUTH FLORIDA (US) | 2011-04-19 | — | — | US | disclosed |
| US-7790905-B2 | Pharmaceutical propylene glycol solvate compositions | MCNEIL-PPC, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| JP-S58113161-A | NOVEL SYNTHETIC METHOD FOR NEGAMYCIN | TEIKOKU HORMONE MFG CO LTD | 1983-07-05 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11654135-B2 | Methods for treating colon cancer with compositions comprising amlexanox and immune checkpoint inhibitors | CD274, MYD88, PDCD1LG2 | GABRR1 1908/4885LMNA 3812/4885CACNA2D1 2672/4885 |
| US-20230381152-A1 | METHODS FOR TREATING COLON CANCER WITH COMPOSITIONS COMPRISING AMLEXANOX AND IMMUNE CHECKPOINT INHIBITORS | CD274, MYD88, PDCD1LG2 | GABRR1 1908/4885LMNA 3812/4885CACNA2D1 2672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.